Keratoconjunctivitis Sicca Clinical Trial
Official title:
Phase 2, Single-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophth Sol'n in the Environment and During Challenge in the Controlled Adverse Environment (CAE) Model for the Treatment of DES
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
Single-center, double-masked, randomized, placebo-controlled study comprising 4 visits over the course of approximately 5 weeks. The study included a 1-week placebo (SkQ1 vehicle) run-in period between Visit 1 and Visit 2, and approximately 28 days of twice daily (BID) dosing (Visit 2 - Visit 4). Qualified subjects were randomized 1:1:1 to receive either 1.55 µg/mL SkQ1 ophthalmic solution, 0.155 µg/mL SkQ1 ophthalmic solution, or placebo (vehicle of SkQ1 ophthalmic solution). The following primary endpoints were tested: - Corneal Fluorescein staining in the inferior region Pre-CAE at Visit 4 (Day 29), as measured by the Ora Calibra Scale in the worst eye at baseline; - Worst dry eye symptom (ocular discomfort, dryness, or grittiness - as determined from subject diary data recorded during the 1-week run-in period between Visit 1 and Visit 2) evaluated over the seven days preceding Visit 4 (not including day of visit) during the treatment period. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT02254265 -
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
|
Phase 2/Phase 3 | |
Completed |
NCT00883649 -
Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
|
N/A | |
Completed |
NCT00128245 -
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
|
Phase 2 | |
Completed |
NCT00717418 -
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
|
N/A | |
Enrolling by invitation |
NCT03436576 -
Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye
|
Phase 3 | |
Completed |
NCT04147650 -
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT01733992 -
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT00987727 -
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
|
Phase 4 | |
Completed |
NCT00788229 -
Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT00554879 -
Acupuncture Treatment of Dry Eye
|
N/A | |
Completed |
NCT00407043 -
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
|
Phase 4 | |
Completed |
NCT00001731 -
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
|
Phase 2 | |
Recruiting |
NCT03953703 -
Levocarnitine for Dry Eye in Sjogren's Syndrome
|
Phase 2 | |
Withdrawn |
NCT03398018 -
Repository Corticotropin Injection in Keratoconjunctivitis Sicca
|
Phase 4 | |
Recruiting |
NCT02066896 -
Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
|
Phase 3 | |
Completed |
NCT02139033 -
A Phase 4 Study Investigating the Efficacy of Retaineā¢ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
|
Phase 4 | |
Terminated |
NCT01213342 -
Omega-3 Fatty Acid Supplements and Dry Eye
|
N/A | |
Completed |
NCT00201955 -
Study of Rebamipide Eye Drops to Treat Dry Eye
|
Phase 3 | |
Completed |
NCT00201981 -
Study of Rebamipide Eye Drops to Treat Dry Eye
|
Phase 3 |